1 IN 15 PATIENTS
PRESCRIBED AN OPIOID MAY GO ON TO LONG-TERM USE OR ABUSE1,2

DePuy Synthes Companies & Pacira Pharmaceuticals, Inc.:
JOIN US AS WE PARTNER TO
HELP COMBAT THE
OPIOID EPIDEMIC

EXPAREL provides:

- 78% reduced opioid consumption3
- 13.6% lower pain intensity scores3
- 10% of patients opioid-free at 72 hours3
- Long-lasting pain control4
- Broad indication for use
- Unique multivesicular formulation

Demonstrated by Phase IV TKA PILLAR Clinical Trial Compared to bupivacaine HCl*

* Rates and types of adverse events were similar between treatment groups. The most common adverse events in the EXPAREL group were nausea, muscle spasms, and vomiting.3

Please refer to Important Safety Information on reverse.
EXPAREL® (bupivacaine liposome injectable suspension) Important Safety Information

**Indication:** EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.

**Important Safety Information:**
- EXPAREL is contraindicated in obstetrical paracervical block anesthesia
- In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting
- EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients
- Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations

**WARNINGS AND PRECAUTIONS SPECIFIC TO EXPAREL**
- EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks, or intravenous or intra-articular use
- Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL

**WARNINGS AND PRECAUTIONS FOR BUPIVACAINE-CONTAINING PRODUCTS**
- **Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesias. CNS reactions are characterized by excitation and/or depression
- **Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias sometimes leading to death
- **Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients
- **Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use

**PLEASE SEE ACCOMPANYING FULL PRESCRIBING INFORMATION FOR EXPAREL.**

**PLEASE CONTACT YOUR DEPUY SYNTHES SALES CONSULTANT FOR MORE INFORMATION.**


The third-party trademarks used herein are the trademarks of their respective owners. © Pacira Pharmaceuticals, Inc. © Depuy Synthes 2017. All rights reserved. PP-EX-US-2817 DSUS/MOC/0517/0731